Nessan Bermingham, President & CEO at Intellia Therapeutics, Inc. (NTLA), sold 673,566 shares at $20.28 ($14.0M) on 2017-12-06, disclosed to the SEC on 2017-12-08.
Open-market sale of $14.0M NTLA by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.28 | 99,033 | $2.0M | 14.3% |
| 2 | $20.28 | 99,033 | $2.0M | 14.3% |
| 3 | $20.84 | 12,467 | $260K | 1.9% |
| 4 | $20.84 | 12,467 | $260K | 1.9% |
| 5 | $21.05 | 103,574 | $2.2M | 15.6% |
| 6 | $21.05 | 103,574 |
| $2.2M |
| 15.6% |
| 7 | $21.46 | 27,566 | $592K | 4.2% |
| 8 | $21.46 | 27,566 | $592K | 4.2% |
| 9 | $20.82 | 94,143 | $2.0M | 14.0% |
| 10 | $20.82 | 94,143 | $2.0M | 14.0% |
| Total | $20.79 avg | 673,566 | $14.0M | 100% |